Results 21 to 30 of about 418,673 (161)

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Cardiovascular Diabetology, 2008
Objective Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic control in Type 2 diabetes.
Tetlow Anthony P, Evans Mark, Woehl Anette, McEwan Philip   +3 more
doaj   +1 more source

Insulin glargine use and breast cancer: a systematic review and meta-analysis

Electronic Physician, 2019
Background: Insulin is widely used in the treatment of diabetes. There is an increasing concern regarding the association between insulin glargine use and breast cancer.
Ibrahim Altedlawi Albalawi, Hyder Osman Mirghani   +1 more
doaj   +1 more source

Special aspects of concentrated insulins: basic characteristics and research findings

Сахарный диабет, 2019
The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e.
Tatiana Y. Demidova, Olga V. Balutina
doaj   +1 more source

An overview of insulin glargine

Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Accordingly, it mimics more closely the natural physiological profile of basal endogenous insulin secretion than do ...
Home PD; Ashwell SG
core   +5 more sources

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling

Frontiers in Endocrinology, 2019
Our aim was to investigate whether human insulin (HI) or insulin glargine treatment could promote the proliferation of thyroid cells and determine the association between type 2 diabetes and thyroid disease.
Xiaoli Sheng, Kannan Yao, Anwen Shao, Sheng Tu, Xinxia Zhang, Ting Chen, Dingguo Yao   +6 more
doaj   +1 more source

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

Cost Effectiveness and Resource Allocation, 2019
Background International guidelines recommend using basal insulin in patients with type-2 diabetes mellitus if glycaemic target cannot be attained on non-insulin anti-diabetic drugs.
E. Lau, A. Salem, J. C. N. Chan, W. Y. So, A. Kong, M. Lamotte, A. Luk   +6 more
doaj   +1 more source

Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model. [PDF]

PLoS ONE, 2018
BackgroundThe manufacture of insulin analogs requires sophisticated production procedures which can lead to differences in the structure, purity, and/or other physiochemical properties of resultant products that can affect their biologic activity.
Ernesto Luna, Pankaj Agrawal, Riyaz Mehta, Maria E Boone, Charlotte Vernhes, Colombe Denys, Robert Small, Bhaswati Mukherjee, Norbert Tennagels, Stefan Maerten, Donald R Drake   +10 more
doaj   +1 more source

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients

BMC Endocrine Disorders, 2012
Background The uncertainties regarding dose similarities between basal long-acting insulin analogues remain. Recent real-world studies indicate dose similarities between insulin detemir and insulin glargine, but further studies are still warranted.
Jakobsen Marie, Dalsgaard Mette, Hørmann Morten, Møller Daniél   +3 more
doaj   +1 more source

Insulin glargine: The first clinically useful extended-action insulin analogue

, 2001
Insulin glargine is a new extended-action insulin analogue, created by recombinant DNA modification of human insulin. Extension of the C-terminal of the B-chain with two arginine residues and the substitution of glycine for asparagine at position A-21 ...
Home PD; Ashwell SG
core   +5 more sources

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints

Frontiers in Pharmacology, 2022
Insulin glargine is a long-acting insulin analog, which plays an important role in the treatment of diabetes mellitus. Biosimilar products of insulin glargine can provide patients with additional safe, high-quality, and potentially cost-effective options
Yiya Wang, Yiya Wang, Ying Zhou, Juefang Ding, Xianjing Li, Fengxue Guo, Jianfei Zhang, Li Ding   +7 more
doaj   +1 more source